Intellia Therapeutics Q3 2023 Earnings Update | CRISPR Gene Editing

Intellia Therapeutics presented its third quarter 2023 earnings update on November 9, 2023, highlighting progress in CRISPR-based gene editing programs including NTLA-2001 for ATTR cardiomyopathy and NTLA-2002 for hereditary angioedema. The presentation covers clinical pipeline advances, research platform updates, and financial results, with expectations to initiate Phase 3 trials in late 2023 and 2024.